Mizuho raised the firm’s price target on Medtronic to $98 from $95 and keeps a Buy rating on the shares. The company’s fiscal Q3 report “hit the market in all the right places,” the analyst tells investors in a research note. The firm says Medtronic’s margin expansion has legs but currency and inflation remain an offset. It believes the company’s revamped portfolio will outweigh 2024 headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic (NYSE:MDT) Soars on Q3 Beat
- Options Volatility and Implied Earnings Moves Today, February 20, 2024
- Medtronic Reorganizes Units and Executives Depart
- Medtronic reports third quarter fiscal 2024 financial results
- Medtronic reports Q3 EPS $1.30, consensus $1.26
Questions or Comments about the article? Write to editor@tipranks.com